Plus Therapeutics, Inc.
PSTV
$5.50
-$0.03-0.54%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 1.03M | 1.37M | 1.40M | 1.39M | 1.06M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.03M | 1.37M | 1.40M | 1.39M | 1.06M |
| Cost of Revenue | 2.87M | 2.94M | 2.44M | 1.25M | 1.76M |
| Gross Profit | -1.84M | -1.57M | -1.04M | 144.00K | -697.00K |
| SG&A Expenses | 5.28M | 4.17M | 3.44M | 1.68M | 2.84M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 8.15M | 7.11M | 5.88M | 2.93M | 4.60M |
| Operating Income | -7.12M | -5.74M | -4.48M | -1.54M | -3.54M |
| Income Before Tax | -6.95M | -5.71M | -4.42M | 5.15M | -17.40M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -6.95M | -5.71M | -4.42M | 5.15M | -17.40M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -6.95M | -5.71M | -4.42M | 5.15M | -17.40M |
| EBIT | -7.12M | -5.74M | -4.48M | -1.54M | -3.54M |
| EBITDA | -7.02M | -5.60M | -4.41M | -1.46M | -3.39M |
| EPS Basic | -1.05 | -1.04 | -1.03 | 0.62 | -29.86 |
| Normalized Basic EPS | -0.65 | -0.65 | -0.64 | 1.66 | -18.67 |
| EPS Diluted | -1.05 | -1.05 | -1.03 | -0.16 | -29.86 |
| Normalized Diluted EPS | -0.65 | -0.65 | -0.64 | 0.38 | -18.67 |
| Average Basic Shares Outstanding | 6.65M | 5.51M | 4.30M | 1.94M | 582.70K |
| Average Diluted Shares Outstanding | 6.65M | 5.51M | 4.30M | 8.37M | 582.70K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |